Home Cart Sign in  
Chemical Structure| 129497-78-5 Chemical Structure| 129497-78-5
Chemical Structure| 129497-78-5

Verteporfin

CAS No.: 129497-78-5

Verteporfin is a YAP inhibitor, which effectively destroys the YAP-TEAD interaction and induces cell apoptosis. At the same time, as an autophagy inhibitor, it specifically blocks the early stage of autophagy by preventing the formation of autophagy. Verteporfin, as a photosensitizer, can generate reactive oxygen species under illumination, and its IC50 value is 0.6nM. Verteporfin has anti-tumor and anti-angiogenesis effects, and can be used for photodynamic therapy and age-related macular degeneration.

Synonyms: CL 318952; BPD-MA; DB00460, CL 318952, BPD-MA, BpdMA, Benzoporphyrin D, Benzoporphyrin derivative monoacid ring A, Verteporfin, Visudyne.

4.5 *For Research Use Only !

Cat. No.: A138297 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÍʶÊÊ Inquiry Inquiry
5mg łďǶÊÊ Inquiry Inquiry
10mg łÇÊò¶ÊÊ Inquiry Inquiry
25mg łËòͶÊÊ Inquiry Inquiry
50mg łÍÊò¶ÊÊ Inquiry Inquiry
100mg łďÊò¶ÊÊ Inquiry Inquiry
250mg łÇËͧ¶ÊÊ Inquiry Inquiry
1g łËóÿ§¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łÍʶÊÊ

  • 5mg

    łďǶÊÊ

  • 10mg

    łÇÊò¶ÊÊ

  • 25mg

    łËòͶÊÊ

  • 50mg

    łÍÊò¶ÊÊ

  • 100mg

    łďÊò¶ÊÊ

  • 250mg

    łÇËͧ¶ÊÊ

  • 1g

    łËóÿ§¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Product Citations      Show More

Akinduro, Oluwaseun O ; Meade, Paola Suarez ; Schiapparelli, Paula ; Whitehead, Rachel ; Tzeng, Stephany Y ; Rosenfeld, Steven S , et al.

Abstract: Chordomas are locally invasive cancers that are highly resistant to radiotherapy. The Brachyury and Yes Associated Protein (YAP) regulatory axis has been implicated as the primary driver of tumorigenicity in chordoma. Here, we aimed to enhance chordoma radiosensitivity by repurposing the FDA-approved YAP inhibitor, Verteporfin. We used five patient-derived chordoma cell lines and generated two YAP1 knockdown cell lines to validate the YAP-targeting phenotype in chordoma. Verteporfin treatment reduced the expression of DNA damage repair proteins and genes. YAP inhibition with either verteporfin or YAP knockdown resulted in enhanced DNA double-stranded breaks after radiation via inhibition of the DNA damage repair pathway and accumulation of cells in the G2M phase. Verteporfin inhibited chordoma tumor growth alone and in combination with radiation in a xenograft mouse model treated with verteporfin loaded microparticles, resulting in sensitization of chordoma tumors to radiation. YAP inhibition with verteporfin renders chordoma more sensitive to radiation via inhibition of the DNA damage repair cascade and accumulation of cells in G2M when they are most susceptible to radiation damage.

Purchased from AmBeed:

Akinduro, Oluwaseun O ; Suarez-Meade, Paola ; Roberts, McKinley ; Tzeng, Stephany Y ; Sarabia-Estrada, Rachel ; Schiapparelli, Paula , et al.

Abstract: Objective: The vertebral column is the most common site for skeletal metastasis, often leading to debilitating pain and weakness. Metastatic cancer has unique genetic drivers that potentiate tumorigenicity. There is an unmet need for novel targeted therapy in patients with spinal metastatic disease. Methods: The authors assessed the effect of verteporfin-induced yes-associated protein (YAP) inhibition on spine metastatic cell tumorigenicity and radiation sensitivity in vitro. Animal studies used a subcutaneous xenograft mouse model to assess the use of systemic intraperitoneal verteporfin (IP-VP) and intratumoral verteporfin microparticles (IT-VP) to inhibit the tumorigenicity of lung and breast spinal metastatic tumors from primary patient-derived tissue. Results: Verteporfin led to a dose-dependent decrease in migration, clonogenicity, and cell viability via inhibition of YAP and downstream effectors cyclin D1, CTGF, TOP2A, ANDRD1, MCL-1, FOSL2, KIF14, and KIF23. This was confirmed with knockdown of YAP. Verteporfin has an additive response when combined with radiation, and knockdown of YAP rendered cells more sensitive to radiation. The addition of verteporfin to YAP knockdown cells did not significantly alter migration, clonogenicity, or cell viability. IP-VP and IT-VP led to diminished tumor growth (p < 0.0001), especially when combined with radiation (p < 0.0001). Tissue analysis revealed diminished expression of YAP (p < 0.0001), MCL-1 (p < 0.0001), and Ki-67 (p < 0.0001) in tissue from verteporfin-treated tumors compared with vehicle-treated tumors. Conclusions: This is the first study to demonstrate that verteporfin-mediated inhibition of YAP leads to diminished tumorigenicity in lung and breast spinal metastatic cancer cells. Targeting of YAP with verteporfin offers promising results that could be translated to human clinical trials.

Keywords: YAP ; breast metastasis ; lung cancer ; microparticles ; oncology ; spine metastasis ; verteporfin ; yes-associated protein

Purchased from AmBeed:

Alternative Products

Product Details of Verteporfin

CAS No. :129497-78-5
Formula : C41H42N4O8
M.W : 718.79
SMILES Code : NONE
Synonyms :
CL 318952; BPD-MA; DB00460, CL 318952, BPD-MA, BpdMA, Benzoporphyrin D, Benzoporphyrin derivative monoacid ring A, Verteporfin, Visudyne.
MDL No. :MFCD28098202

Safety of Verteporfin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Verteporfin

Hippo

Isoform Comparison

Biological Activity

Target
  • VDA

In Vitro:

Cell Line
Concentration Treated Time Description Reference
hiPSC-CMs 0.1, 1, 10, 50, 100 μM 24 h To pharmacologically inhibit YAP activity and assess its impact on hiPSC-CMs proliferation. Results showed that verteporfin treatment did not significantly reduce hiPSC-CMs proliferation. PMC7334437
Hepa1-6 cells 0.25 to 1 μM 48 h Inhibition of YAP/TEAD complex, reduction of PAI-1 expression and secretion PMC7583285
Sk-Hep1 cells 0.25 to 1 μM 48 h Inhibition of YAP/TEAD complex, reduction of PAI-1 expression and secretion PMC7583285
HEK293A cells 6.45 µM 18 h Inhibition of the YAP-TEAD interaction reduces expression of CAV1 and CAVIN1 PMC6345631
Panc-1 cells 100 nM 48 h To evaluate the effect of Verteporfin on YAP1-TEAD interaction, results showed that Verteporfin significantly reduced the expression of YAP1 target genes. PMC7017485
4T1 TNBC cells 0.25 μM 90 min The combination of PDT with 5-ADC exerted a synergistic cytotoxic effect on 4T1 cells in vitro, significantly reducing cell proliferation and viability. PMC10664979
4T1 TNBC cells 0.15 μM 90 min The combination of PDT with 5-ADC exerted a synergistic cytotoxic effect on 4T1 cells in vitro, significantly reducing cell proliferation and viability. PMC10664979
Huh-7 cells 1 μM To validate the sensitivity of Huh-7 cells to Verteporfin after ARID1A silencing, results showed that ARID1A-silenced Huh-7 cells were more sensitive to Verteporfin. PMC9751287
HLE cells 1 μM To validate the sensitivity of HLE cells to Verteporfin after ARID1A silencing, results showed that ARID1A-silenced HLE cells were more sensitive to Verteporfin. PMC9751287
Huh-7 1μM To validate the sensitivity of ARID1A-silenced cells to Verteporfin. PMC9751287
HLE 1μM To validate the sensitivity of ARID1A-silenced cells to Verteporfin. PMC9751287

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Balb/c mice 4T1 breast cancer model Intravenous injection 15mg/kg Single dose, lasting 5 days The combination of PDT with 5-ADC significantly increased the expression of splenic CD4+ and CD8+ T cells in vivo, suppressing tumor metastasis. PMC10664979
Mice B16 melanoma model Intraperitoneal injection 2 mg/mouse Every two days Verteporfin combined with anti-PD-1 antibody or GM-Vac significantly suppressed tumor growth and enhanced the proportion of IFNγ-producing CD8+ and CD4+ T cells in the tumor microenvironment. PMC6481611
Mice PVR mouse model Intraperitoneal injection 100 mg/kg Every other day for 4 weeks Verteporfin attenuated the upregulation of Cyclin D1, C-Myc, and Bcl-xl proteins in the PVR mouse model by inhibiting the YAP signaling pathway, indicating its therapeutic potential for PVR. PMC9344224

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00211484 Age-Related Macular Degenerati... More >>ons. Subfoveal Neovascularization. Less << Phase 2 Completed - United States, New York ... More >> Manhattan Eye, Ear & Throat Hospital New York, New York, United States, 10021 Less <<
NCT02587767 Acute Central Serous Chorioret... More >>inopathy Less << Not Applicable Active, not recruiting December 2018 China, Guangdong ... More >> Zhongshan Ophthalmic Center, Sun Yat-sen University Guangzhou, Guangdong, China, 510060 Less <<
NCT02072408 Polypoidal Choroidal Vasculopa... More >>thy Without Active Polyp Less << Phase 4 Completed - Korea, Republic of ... More >> Seoul National University Bundang Hospital Seongnam, Gyunggi-do, Korea, Republic of Konyang University Kim's Eye Hospital Seoul, Korea, Republic of Samsung Medical Center Seoul, Korea, Republic of Less <<
NCT00043680 Macular Degeneration Phase 2 Completed - United States, Maryland ... More >> National Eye Institute (NEI) Bethesda, Maryland, United States, 20892 Less <<
NCT03497000 Central Serous Chorioretinopat... More >>hy Tomography, Optical Coherence Less << Not Applicable Completed - China, Beijing ... More >> People's Hospital of Peking University Beijing, Beijing, China, 100044 Less <<
NCT01162746 Age-Related Macular Degenerati... More >>on Neovascularization, Choroidal Less << Phase 2 Completed - Austria ... More >> Department of Ophthalmology, Medical University of Vienna Vienna, Austria, 1090 Less <<
NCT01434095 Chronic Central Serous Chorior... More >>etinopathy Less << Not Applicable Completed - Japan ... More >> Department of Ophthalmology, Surugadai Nihon University Hospital Chiyoda-ku, Tokyo, Japan, 101-8309 Less <<
NCT01971190 Central Serous Chorioretinopat... More >>hy Less << Phase 2 Completed - Korea, Republic of ... More >> Chungbuk national hospital ChungJu, Korea, Republic of Gangneung asan hospital Gangneung, Korea, Republic of Seoul national university Bundang Hospital Ilsan, Korea, Republic of Asan medical center Seoul, Korea, Republic of, 138736 Kim's Eye Hospital Seoul, Korea, Republic of, 150-034 Samsung seoul hospital Seoul, Korea, Republic of Less <<
NCT00569569 Age Related Macular Degenerati... More >>on Less << Phase 2 Phase 3 Completed - -
NCT00556946 Port Wine Stains Not Applicable Completed - United States, California ... More >> Beckman Laser Medical Clinic,University Irvine, California, United States, 02612 Less <<
NCT00556946 - Completed - -
NCT01027468 Neovascular Age-related Macula... More >>r Degeneration Less << Not Applicable Completed - -
NCT01630863 Central Serous Chorioretinopat... More >>hy Less << Not Applicable Unknown March 2015 Korea, Republic of ... More >> Yeungnam University College of Medicine Recruiting Daegu, Korea, Republic of Contact: Min Sagong    82-53-620-4191    msagong@ynu.ac.kr    Principal Investigator: Min Sagong Less <<
NCT00391144 Choroidal Neovascularization S... More >>econdary to Pattern Dystrophy Less << Phase 2 Phase 3 Unknown - Italy ... More >> Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste Recruiting Trieste, TS, Italy, 34129 Contact: Giuseppe Ravalico, MD    +39 040 772449    giuseppe.ravalico@aots.sanita.fvg.it Less <<
NCT03079141 Chronic Central Serous Chorior... More >>etinopathy Less << Phase 4 Recruiting February 2021 Netherlands ... More >> Academic Medical Center Recruiting Amsterdam, Netherlands Contact: Reinier O Schlingemann, MD, PhD          Contact: Monique Wezel          Leiden University Medical Center Recruiting Leiden, Netherlands Contact: Elon H van Dijk, MD    +31715299431    ehcvandijk@lumc.nl    Contact: Thomas J van Rijssen, MD       t.j.van_rijssen@lumc.nl    Radboud University Medical Center Recruiting Nijmegen, Netherlands Contact: Carel B Hoyng, MD, PhD          Contact: Asha Kalisingh Less <<
NCT00100009 Macular Degeneration Phase 3 Completed - -
NCT00523406 Macular Degeneration Phase 3 Completed - Austria ... More >> Medical University of Vienna, Department of Ophthalmology Vienna, Austria, 1090 Less <<
NCT02452840 - Recruiting October 2022 United States, North Carolina ... More >> Duke Eye Center Recruiting Durham, North Carolina, United States, 27710 Contact: Ana Garcia-Turner    919-681-8872       Principal Investigator: Scott Cousins, MD          Sub-Investigator: Priyatham Mettu, MD Less <<
NCT00464347 Age-Related Macular Degenerati... More >>on Less << Phase 2 Terminated(Study was terminate... More >>d because of poor enrollment.) Less << - United States, Florida ... More >> Retinal Group of Florida Ft. Lauderdale, Florida, United States, 33334 Central Florida Retina- Orlando Orlando, Florida, United States, 32746 Retina Specialists Pensacola, Florida, United States, 32503 United States, Maryland Elman Retina Group- Baltimore Baltimore, Maryland, United States, 21237 United States, Michigan Associated Retinal Consulants Grand Rapids, Michigan, United States, 49546 United States, Minnesota VitroRetinal Surgery Minneapolis, Minnesota, United States, 55435 United States, North Carolina Duke University Eye Center Durham, North Carolina, United States, 27710 United States, South Carolina Palmetto Retina Center Columbia, South Carolina, United States, 29204 United States, Tennessee Southeastern Retina Associates Knoxville, Tennessee, United States, 37909 United States, Texas Texas Retina Associates-Arlington Arlington, Texas, United States, 76012 Texas Retina Associates-Dallas Dallas, Texas, United States, 85231 Less <<
NCT01027468 - Completed - -
NCT00138632 Wet Age-Related Macular Degene... More >>ration Less << Phase 1 Phase 2 Completed - United States, California ... More >> Retina-Vitreous Associates Medical Group Beverly Hills, California, United States, 90211 United States, Colorado Porter Adventist Hospital, Eye Lab Denver, Colorado, United States, 80210 United States, Florida USF Eye Institute Tampa, Florida, United States, 33612-4742 United States, Illinois Springfield Clinic, LLP Springfield, Illinois, United States, 62701 United States, Maryland Wilmer Eye Institute Baltimore, Maryland, United States, 21287 United States, Massachusetts Lahey Clinic Medical Center, Eye institute Peabody, Massachusetts, United States, 01960 United States, South Dakota Black Hills Regional Eye Institute Rapid City, South Dakota, United States, 05770 Australia, New South Wales Novartis Investigative Site Parramatta, New South Wales, Australia, 2150 Novartis Investigational Site Sydney, New South Wales, Australia, 2000 Novartis Investigative Site Westmead, New South Wales, Australia, 2145 Australia, Victoria Novartis Investigative Site East Melbourne, Victoria, Australia, 3002 Less <<
NCT00148551 Age-Related Macular Degenerati... More >>on Less << Phase 2 Phase 3 Unknown March 2008 Canada, British Columbia ... More >> Eye Care Centre Vancouver, British Columbia, Canada Less <<
NCT02799992 Chronic Central Serous Chorior... More >>etinopathy Less << Not Applicable Unknown September 2016 -
NCT00211419 Maculopathy, Age-Related Phase 1 Completed - United States, New York ... More >> Manhattan Eye, Ear & Throat Hospital New York, New York, United States, 10021 Less <<
NCT00211458 Macular Degeneration Phase 2 Completed - United States, New York ... More >> Manhattan Eye, Ear & Throat Hospital New York, New York, United States, 10021 Less <<
NCT00527475 Macular Degeneration Phase 2 Completed - United States, California ... More >> California Retina Consultants & Research Foundation Santa Barbara, California, United States, 93103 United States, Michigan Associated Retinal Consultants Ann Arbor, Michigan, United States, 49301 United States, Texas Texas Retina Associates Arlington, Texas, United States, 76012 Less <<
NCT00802126 Myopia Phase 1 Completed - Italy ... More >> Ophthalmology Department SUN Napoli, Italy, 80100 Less <<
NCT00370539 Neovascular Age-Related Macula... More >>r Degeneration Less << Phase 3 Unknown - Iran, Islamic Republic of ... More >> Hamid Ahmadieh, MD Recruiting Tehran, Iran, Islamic Republic of, 16666 Contact: Hamid Ahmadieh, MD    +98 21 22585952    hahmadieh@hotmail.com Less <<
NCT01797861 Chronic Central Serous Chorior... More >>etinopathy Less << Phase 4 Completed - France ... More >> Creteil University Eye Clinic Paris, France, 94010 Germany Cologne University Eye Clinic Cologne, Germany, 50937 Netherlands Leiden University Medical Center Leiden, Netherlands Radboud University Nijmegen Medical Centre, Institute of Ophthalmology Nijmegen, Netherlands, 6500 HB United Kingdom Oxford University Eye Hospital, John Radcliffe Hospital Oxford, United Kingdom, OX3 9DU Less <<
NCT01482910 Macular Degeneration Phase 3 Completed - China, Guangdong ... More >> Guangzhou, Guangdong, China, 510060 China, Hunan Changsha, Hunan, China, 410011 China, Shaanxi Xi'an, Shaanxi, China, 710032 China, Shandong Qingdao, Shandong, China China, Sichuan Chengdu, Sichuan, China, 610041 China, Zhejiang Hangzhou, Zhejiang, China, 310003 Hangzhou, Zhejiang, China, 310009 Wenzhou, Zhejiang, China China Beijing, China, 100044 Beijing, China, 100083 Beijing, China, 100730 Beijing, China, 2000080 Shanghai, China Tianjin, China, 300384 Less <<
NCT01025063 - Completed - -
NCT00002647 Brain and Central Nervous Syst... More >>em Tumors Metastatic Cancer Less << Phase 1 Unknown - United States, Wisconsin ... More >> Medical College of Wisconsin Cancer Center Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Clinical Trials Office - Medical College of Wisconsin Cancer C    414-805-4380       Midwest Children's Cancer Center at Children's Hospital of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Bruce A. Kaufman, MD    414-266-2000 Less <<
NCT01482910 - Completed - -
NCT03692169 - Recruiting June 30, 2019 China, Guangdong ... More >> Fabao Xu Completed Guangzhou, Guangdong, China, 510000 Zhongshan Ophthalmic Center, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510000 Less <<
NCT00527475 - Completed - -
NCT02081339 - Recruiting March 2024 Japan ... More >> Kyoto University Graduate School of Medicine Recruiting Kyoto, Japan, 606-8507 Contact: Misao Ogaki    +81-75-751-3248    misao@kuhp.kyoto-u.ac.jp    Principal Investigator: Akitaka Tsujikawa, MD Less <<
NCT01256580 Choroidal Neovascularization ... More >> Myopia Punctate Inner Choroidopathy (PIC) Multifocal Choroiditis Ocular Histoplasmosis Syndrome Central Serous Chorioretinopathy (CSC) Angioid Streaks Trauma, or Hereditary Eye Diseases Less << Not Applicable Withdrawn(Lack of eligible sub... More >>jects.) Less << September 2013 -
NCT00967850 Myopia Choroi... More >>dal Neovascularization Less << Phase 3 Completed - Spain ... More >> INGO Santiago de Compostela, La Coruña, Spain, 15706 Hospital General Reina Sofía Espinardo, Murcia, Spain, 30100 Clínica Universitaria de Navarra Pamplona, Navarra, Spain, 31080 Instituto Oftalmológico de Alicante Alicante, Spain, 03015 Hospital de la Vall d´Hebron Barcelona, Spain, 08022 Hospital Clínico San Carlos Madrid, Spain, 28010 IOBA - Instituto Universitario de Oftalmobiología Aplicada Valladolid, Spain, 47011 Less <<
NCT00007969 Melanoma (Skin) Phase 1 Phase 2 Completed - United States, Colorado ... More >> University of Colorado Cancer Center Denver, Colorado, United States, 80010 United States, Florida Mount Sinai Comprehensive Cancer Center at Aventura Aventura, Florida, United States, 33180 Mount Sinai Comprehensive Cancer Center Miami Beach, Florida, United States, 33140 United States, Michigan Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201-1379 United States, Missouri Missouri Baptist Cancer Center Saint Louis, Missouri, United States, 63131 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15213-3489 Less <<
NCT00930189 Subfoveal Choroidal Neovascula... More >>rization Less << Phase 2 Phase 3 Unknown September 2006 Mexico ... More >> Centro Medico Isemmym Recruiting Metepec, Estado-de-Mexico, Mexico, 52140 Contact: Rosa M Romero, MD    7221600451    rromerocastro@yahoo.com    Contact: Hugo Quiroz-Mercado, MD    52555108414000 ext 1171    retinamex@yahoo.com    Sub-Investigator: Gerardo Monares, MD          Sub-Investigator: Alfredo Morales, MD          Sub-Investigator: Juan-Carlos De-la Luz, MD          Sub-Investigator: Antonio Niño, MD          Sub-Investigator: Gonzalo Padilla, MD          Sub-Investigator: Hugo Quiroz-Mercado, MD Less <<
NCT02120950 Neovascular Macular Degenerati... More >>on Less << Phase 4 Active, not recruiting July 2017 -
NCT00390208 Age Related Macular Degenerati... More >>on Less << Phase 2 Completed - United States, California ... More >> Bay Area Retina Associates Castro Valley, California, United States, 94546 Bay Area Retina Associates Walnut Creek, California, United States, 94598 United States, Georgia Georgia Retina Riverdale, Georgia, United States, 30274 United States, Ohio Retina Vitreous Associates Toledo, Ohio, United States, 43608 Less <<
NCT00457678 Age Related Macular Degenerati... More >>on Less << Phase 2 Withdrawn(Site did not enroll ... More >>any patients to the study.) Less << - -
NCT00813891 Macular Degeneration ... More >> Visual Acuity Less << Phase 4 Unknown December 2009 Canada, Quebec ... More >> The Royal Victoria Hospital and the Montreal Retinal Institute Not yet recruiting Montreal, Quebec, Canada, H3Z 1P4 Less <<
NCT00726973 Macular Edema Not Applicable Withdrawn(Unable to recruit st... More >>udy participants) Less << July 2012 -
NCT01032109 Age-related Macular Degenerati... More >>on Less << Not Applicable Completed - Japan ... More >> Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences, Kumamoto University Kumamoto, Japan, 860-8556 Less <<
NCT00331435 Age Related Macular Degenerati... More >>on Less << Phase 4 Completed - Japan ... More >> Nagoya City University Hospital Aichi, Japan Nagoya University Aichi, Japan Kyushu University Fukuoka, Japan, 812-0054 Fukushima Medical University School of Medicine Fukushima, Japan, 960-1295 Gunma University Gunma, Japan Kagawa University Kagawa, Japan, 761-0793 Kyoto University Kyoto, Japan, 606-8507 Osaka University Osaka, Japan, 565-0871 Kansai Medical University Takii Hospital Osaka, Japan, 570-8507 Kansai Medical University Hirakata Hospital Osaka, Japan, 573-1191 Sapporo City general hospital Sapporo, Japan, 060-8604 Shiga University of Medical Science Shiga, Japan Surugadai Nihon University Hospital Tokyo, Japan, 101-8309 Kyorin University Tokyo, Japan, 181-8611 Toho University Tokyo, Japan Tokyo University Ohashi Medical Center Tokyo, Japan Yamanashi University Yamanashi, Japan Less <<
NCT00696592 Neovascular Age-Related Macula... More >>r Degeneration Less << Phase 2 Unknown - Italy ... More >> Department of Ophthalmology, University of Padova Recruiting Padova, PD, Italy, 35100 Contact: Giuseppe Lo Giudice, M.D.    0039049 2050153    gvofta@libero.it    Principal Investigator: Stefano Piermarocchi, M.D. Less <<
NCT01666236 Choroidal Neovascularization ... More >> Retinal Pigment Epithelial Detachment Less << Phase 4 Withdrawn(Lack of resources) September 2014 Brazil ... More >> Universidade Federal de São Paulo - Escola Paulista de Medicina São Paulo, SP, Brazil, 04038-034 Less <<
NCT00347399 Age Related Macular Degenerati... More >>on Less << Phase 2 Unknown - Mexico ... More >> Hospital Luis Sanchez Bulnes Recruiting Mexico city, DF, Mexico, 04030 Contact: Hugo Quiroz-Mercado, MD    525510841400    retinamex@yahoo.com    Principal Investigator: Maura L Abraham Marin, MD Less <<
NCT00413829 Age Related Macular Degenerati... More >>on Less << Phase 2 Completed - Switzerland ... More >> Klinik und Poliklinik fuer Augenheilkunde, Inselspital Bern, Switzerland Less <<
NCT01574430 Central Serous Chorioretinopat... More >>hy Less << Phase 4 Completed - China, Beijing ... More >> People's Hospital of Peking University Beijing, Beijing, China, 100044 Less <<
NCT02464761 Vertebral Metastases Phase 1 Completed - Canada, Ontario ... More >> Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 Less <<
NCT00056823 Age-Related Maculopathy Phase 1 Phase 2 Completed - -
NCT02321267 Macular Disease Phase 4 Recruiting December 2024 Japan ... More >> Kagawa University Faculty of Medicine Recruiting Miki, Kagawa, Japan, 761-0793 Contact    +81878912211    chosa@med.kagawa-u.ac.jp Less <<
NCT01746875 Macular Degeneration ... More >> Retinal Detachment Less << Not Applicable Terminated(treatment effects n... More >>ot as desired) Less << - Norway ... More >> Department of Neuroscience, NTNU Trondheim, Norway, 7489 Less <<
NCT00041483 Macular Degeneration Phase 3 Completed - United States, Texas ... More >> Contact Alcon Call Center for Trial Locations Ft. Worth, Texas, United States, 76134 Less <<
NCT00546936 Presumed Ocular Histoplasmosis... More >> (POHS) Less << Phase 2 Unknown April 2010 United States, Indiana ... More >> Macula-Retina-Vitreous Service, Midwest Eye Institute Recruiting Indianapolis, Indiana, United States, 46280 Contact: Neelam Thukral    317-805-2152    neelamt@midwest.com    Principal Investigator: Thomas Ciulla, MD          United States, Missouri Barnes Retina Institute Recruiting St. Louis, Missouri, United States, 63110 Contact: Ginny S Nobel, COT    314-367-1278 ext 2305    bristudy@barnesretinainstitute.com    Contact: Carol L Walters, COT    314-367-2287 ext 2312    bristudy@barnesretinainstitute.com    Principal Investigator: Kevin J Blinder, MD Less <<
NCT02457026 Neovascular Age-related Macula... More >>r Degeneration Less << Not Applicable Withdrawn January 2018 United States, North Carolina ... More >> Duke Eye Center Durham, North Carolina, United States, 27710 Less <<
NCT01325181 Chronic Central Serous Chorior... More >>etinopathy Less << Phase 1 Phase 2 Completed - Korea, Republic of ... More >> • Department of Ophthalmology, Seoul National University College of Medicine Seoul, Gyeonggi-do, Korea, Republic of Less <<
NCT01360151 Polypoidal Choroidal Vasculopa... More >>thy Less << Not Applicable Unknown May 2011 Korea, Republic of ... More >> Won Ki Lee Recruiting Seoul, Korea, Republic of Contact: Won Ki Lee, MD, PhD    82-2-10-3265-1262    wklee@catholic.ac.kr    Contact: Mee Yon Lee, MD    82-10-3230-1863    deenie@daum.net Less <<
NCT03459144 Polypoidal Choroidal Vasculopa... More >>thy Less << Not Applicable Completed - China, Guangdong ... More >> Zhongshan Ophthalmic Center Guangzhou, Guangdong, China, 510060 Less <<
NCT01325181 - Completed - -
NCT02495181 Polypoidal Choroidal Vasculopa... More >>thy Less << Phase 4 Recruiting March 2020 Portugal ... More >> Hospital de Braga Recruiting Braga, Portugal, 4710-243 Contact: Luís Mendonça          Hospital de Braga Recruiting Braga, Portugal Contact: Luís Mendonça       luismendonc@gmail.com    AIBILI - Centro de Ensaios Clínicos Recruiting Coimbra, Portugal, 3000-548 Coimbra Contact: Rufino Silva          Espaço Médico de Coimbra Recruiting Coimbra, Portugal, 3030-163 Contact: João Figueira          Centro Hospitalar de Leiria Recruiting Leiria, Portugal, 2400-171 Contact: João Paulo Castro Sousa          IRL - Instituto de Retina e Diabetes de Lisboa Recruiting Lisboa, Portugal, 1050-085 Lisboa Contact: Paulo Rosa          Instituto de Microcirurgia Ocular Recruiting Lisboa, Portugal, 1600-209 Contact: José Roque          Centro Hospitgalar de Lisboa Norte, EPE - Hospital de Santa Maria Recruiting Lisboa, Portugal, 1649-035 Contact: Sara Vaz-Pereira          Hospital de Vila Franca de Xira - Serviço de Oftalmologia Recruiting Lisboa, Portugal, 2600-009 Contact: Miguel Amaro          Instituto de Oftalmologia Dr. Gama Pinto Recruiting Lisboa, Portugal Contact: Victor Ágoas       vagoas@igpinto.min-saude.pt    Centro Hospitalar do Porto- Hospital de Santo António Recruiting Porto, Portugal, 4099-001 Contact: Angelina Meireles          Centro Hospitalar de São João, EPE - Serviço de Oftalmologia Recruiting Porto, Portugal, 4200-319 Contact: ângela Carneiro          Spain Unidade Clinica de Retina Recruiting Albacete, Spain Contact: Carlos Cava       ccavavalenciano@yahoo.es    Bellvitge University Hospital Recruiting Barcelona, Spain Contact: Luis Arias       luisariasbarquet@gmail.com    Centro de Oftalmología Barraquer Recruiting Barcelona, Spain Contact: Sonia Viver       docsonia@barraquer.com    Instituto de Microcirugia Ocular Recruiting Barcelona, Spain Contact: Anniken Bures       bures@imo.es    Vall d'Hebron Hospital Recruiting Barcelona, Spain Contact: Laura Distefano       laura.distefano@outlook.com    Hospital Insular de Gran Canaria Recruiting Las Palmas, Spain Contact: Francisco Cabrera López          Instituto Oftalmológico Fernandez-Vega Recruiting Oviedo, Spain Contact: Alvaro Fernandez-Vega Sanz Vega Sanz       investigacion@fernandez-vega.com Less <<
NCT00423189 Age-Related Macular Degenerati... More >>on Less << Phase 4 Terminated(Lack of efficacy) - United States, Texas ... More >> Vitreoretinal Consultants Houston, Texas, United States, 77030 Less <<
NCT00061594 Macular Degeneration Phase 3 Completed - -
NCT00094120 Macular Degeneration Phase 2 Terminated - United States, Pennsylvania ... More >> Genaera Corporation Plymouth Meeting, Pennsylvania, United States, 19462 Less <<
NCT00455871 Age-Related Macular Degenerati... More >>on Less << Not Applicable Unknown October 2010 United States, Missouri ... More >> Barnes Retina Institute Recruiting St. Louis, Missouri, United States, 63110 Principal Investigator: Gaurav K Shah, MD Less <<
NCT00570193 Choroidal Neovascularization ... More >> Macular Degeneration Less << Phase 1 Phase 2 Completed - -
NCT00211445 Chronic Central Serous Chorior... More >>etinopathy Less << Phase 2 Completed - United States, New York ... More >> Manhattan Eye, Ear & Throat Hospital New York, New York, United States, 10021 Less <<
NCT02702700 Pleural Effusion, Malignant Phase 1 Recruiting June 2019 Switzerland ... More >> Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV) Recruiting Lausanne, Vaud (VD), Switzerland, 1011 Contact: Solange Peters, MD-PhD    +41 21 314 44 62    solange.peters@chuv.ch Less <<
NCT01217944 Pathological Myopia Phase 3 Completed - -
NCT00140803 Age-Related Macular Degenerati... More >>on Less << Phase 2 Completed - United States, New York ... More >> Manhattan Eye, Ear & Throat Hospital New York, New York, United States, 10021 Canada, British Columbia Vh/UBC Eye Care Centre Vancouver, British Columbia, Canada, V5Z 3N9 Less <<
NCT00135837 Age-Related Macular Degenerati... More >>on Less << Phase 4 Completed - Switzerland ... More >> Novartis Basel, Switzerland Less <<
NCT00680498 Age-Related Macular Degenerati... More >>on Less << Phase 4 Completed - United States, Illinois ... More >> Illinois Retina Associates Oak Park, Illinois, United States, 60304 Less <<
NCT01217944 - Completed - -
NCT03033225 Pancreatic Cancer Non-Resectab... More >>le Less << Phase 2 Recruiting January 2022 United States, Florida ... More >> Mayo Clinic in Florida Recruiting Jacksonville, Florida, United States, 32224 Contact: Betsy Cayer       cayer.frances@mayo.edu    United States, Minnesota Mayo Clinic in Rochester Recruiting Rochester, Minnesota, United States, 55905 Contact: Lori S Lutzke    507-255-7495    lutzke.lori@mayo.edu    Contact: James Allen       Allen.James1@mayo.edu Less <<
NCT00390026 Age-Related Macular Degenerati... More >>on Less << Phase 3 Withdrawn(Lucentis, a treatmen... More >>t superior to PDT, has become available i Sweden.) Less << - Sweden ... More >> S:t Eriks Eye Hospital Stockholm, Sweden, SE-11282 Less <<
NCT00471406 Corneal Neovascularization Not Applicable Completed - -
NCT00492284 - Completed - -
NCT00288561 Age-Related Macular Degenerati... More >>on (ARMD) Less << Phase 2 Completed - Switzerland ... More >> Novartis Basel, Switzerland Less <<
NCT00121407 Macular Degeneration Phase 3 Completed - -
NCT00492284 Choroidal Neovascularization ... More >> Macular Degeneration Less << Phase 2 Completed - -
NCT01570608 Age Related Macular Degenerati... More >>on Less << Phase 3 Completed - Austria ... More >> Department of OPhthalmology Medical center east Vienna, Austria, A1030 Department of Ophthalmology Rudolf foundation Clinic Vienna, Austria, A1030 Department of Ophthalmology, Hospital Hietzing Vienna, Austria, A1030 Less <<
NCT02821520 Polypoidal Choroidal Vasculopa... More >>thy Less << Phase 4 Recruiting December 2019 China, Zhejiang ... More >> The Eye Hospital of Wenzhou Medical University Recruiting Wenzhou, Zhejiang, China, 325000 Contact: Zuhua Sun, master    86-577-88068855    susan0402@163.com    Principal Investigator: Xiaoling Liu, professor Less <<
NCT02939274 Metastatic Breast Cancer Phase 2 Recruiting December 2019 United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Steven J Isakoff, MD PhD    617-726-4920       Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Beth Overmoyer, MD    617-632-3800 Less <<
NCT00134667 Age-Related Macular Degenerati... More >>on Less << Phase 4 Terminated - United States, Arizona ... More >> Retina Centers, P.C., Northwest Location Tucson, Arizona, United States, 85704-5614 Less <<
NCT00426998 Choroidal Neovascularization ... More >> Macular Degeneration Less << Phase 2 Completed - United States, California ... More >> Retinal Consultants Medical Group, Inc. Sacramento, California, United States, 95819 Less <<
NCT00423189 - Terminated(Lack of efficacy) - -
NCT01019668 Central Serous Chorioretinopat... More >>hy Less << Not Applicable Completed - Taiwan ... More >> Shin Kong Wu Ho-Su Memorial Hospital Taipei, Taiwan, 111 Less <<
NCT01968486 Myopia, Degenerative Phase 1 Completed - -
NCT00403442 Macular Degeneration Phase 1 Terminated - United States, New York ... More >> Vitreous Retina Macula Consultants of New York, P.C. New York, New York, United States, 10022 Less <<
NCT00049959 Basal Cell Carcinoma ... More >> Nevoid Basal Cell Carcinoma Syndrome Gorlin Syndrome Less << Phase 3 Terminated - -
NCT00242580 Macular Degeneration ... More >> Choroidal Neovascularization Less << Phase 3 Completed - United States, Texas ... More >> Novartis Investigational Site Austin, Texas, United States, 78793 Less <<
NCT00429962 Choroidal Neovascularization ... More >> Age-Related Macular Degeneration Less << Phase 3 Completed - Switzerland ... More >> University Eye Clinic Basel, Basel-Stadt, Switzerland, 4031 Less <<
NCT00242580 - Completed - -
NCT01974622 Retinal Vascular Disorders Not Applicable Unknown June 2015 United States, New York ... More >> Vitreous Retina Macula Consultants of New York Recruiting New York, New York, United States, 10022 Contact: Lawrence A. Yannuzzi, M.D.    212-605-3777    layannuzzi@gmail.com    Contact: Irene Barbazetto, M.D.    (212) 861-9797    ibarbazetto@gmail.com    Principal Investigator: Lawrence A. Yannuzzi, M.D.          Sub-Investigator: Irene Barbazetto, M.D. Less <<
NCT00473642 Age-Related Maculopathy ... More >> Choroidal Neovascularization Less << Phase 4 Completed - United States, Oklahoma ... More >> Eagle Mountain Vision Tulsa, Oklahoma, United States, 74132 Less <<
NCT00473642 - Completed - -
NCT01922102 Visual Impairment Due to Choro... More >>idal Neovascularization Secondary to Pathologic Myopia Less << Phase 3 Completed - -
NCT00729846 - Completed - -
NCT00729846 Age Related Macular Degenerati... More >>on Choroidal Neovascularization Macular Edema Less << Phase 2 Completed - United States, California ... More >> California Retina Consultants Bakersfield, California, United States, 93309 California Retina Consultants Santa Barbara, California, United States, 93103 Less <<
NCT00967213 Neovascular Age-related Macula... More >>r Degeneration Less << Phase 3 Completed - Korea, Republic of ... More >> Dept. of Ophthalmology, KyungHee Medical Center, #1 Hoegi, Dongdaemun-gu Seoul, Korea, Republic of, 130-702 Less <<
NCT00359164 Macular Degeneration Phase 2 Completed - Canada, British Columbia ... More >> Vancouver General Hospital Eye Care Centre (UBC) Vancouver, British Columbia, Canada, V5Z 3N9 Less <<
NCT00436553 Macular Degeneration ... More >> Choroidal Neovascularization Less << Phase 3 Completed - -
NCT01846273 Age-related Macular Degenerati... More >>on Polypoidal Choroidal Vasculopathy PCV Less << Phase 4 Completed - -
NCT00436553 - Completed - -
NCT00433017 Macular Degeneration ... More >> Choroidal Neovascularization Less << Phase 2 Phase 3 Terminated(Study was terminate... More >>d based on the results of analyses performed as planned at Month 12.) Less << - Austria ... More >> Novartis Investigative site Wien, Austria Belgium Novartis Investigative site Antwerpen, Belgium Denmark Novartis Investigative site Aalborg, Denmark France Novartis Investigative site Creteil, France Germany Novartis Investigative site Regensburg, Germany Hungary Novartis Investigative site Budapest, Hungary Italy Novartis Investigative site Firenze, Italy Netherlands Novartis Investigative site Rotterdam, Netherlands Poland Novartis Investigative site Warszawa, Poland Spain Novartis Investigative site Madrid, Spain Switzerland Novartis Investigative site Geneve, Switzerland United Kingdom Novartis Investigative site Manchester, United Kingdom Less <<
NCT00574093 Neovascular Age Related Macula... More >>r Degeneration Less << Phase 2 Completed - Italy ... More >> Fondazione G.B.Bietti-IRCCS Rome, Italy, 00198 Less <<
NCT00674323 Polypoidal Choroidal Vasculopa... More >>thy Less << Phase 4 Completed - Hong Kong ... More >> Novartis Investigative Site Hong Kong, Hong Kong Korea, Republic of Novartis Investigative Site Seoul, Korea, Republic of Singapore Novartis Investigative Site Singapore, Singapore Taiwan Novartis Investigative Site Taipei, Taiwan Thailand Novartis Investigative Site Bangkok, Thailand Less <<
NCT00674323 - Completed - -
NCT02872064 Breast Neoplasms COMPLETED 2025-12-17 Royal Free Hospital, London, N... More >>W3 2QG, United Kingdom Less <<
NCT03067051 Recurrent Prostate Cancer Phase 1 Recruiting December 31, 2020 United States, Pennsylvania ... More >> Keith Cengel Not yet recruiting Philadelphia, Pennsylvania, United States, 19104-6205 Contact: Keith Cengel, MD          Contact: Sally Mcnulty, RN          Canada, Ontario Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, ON M5G 2M9 Contact: Neil Fleshner, MD          United Kingdom Reader in Urology, University College London & Honorary Consultant Urological Surgeon, University College London Hospitals Trust Recruiting London, United Kingdom, W1W 7TS Contact: Caroline Moore, MD          Contact: Rebecca Scott, RN Less <<
NCT00433017 - Terminated(Study was terminate... More >>d based on the results of analyses performed as planned at Month 12.) Less << - -
NCT05589974 Central Serous Chorioretinopat... More >>hy Less << RECRUITING 2026-07-31 Stavanger University Hospital,... More >> Department of Ophthalmology, Stavanger, 4016, Norway Less <<
NCT04590664 Glioblastoma|Recurrent Gliobla... More >>stoma Less << PHASE1|PHASE2 RECRUITING 2025-08-15 Emory University Hospital/Wins... More >>hip Cancer Institute, Atlanta, Georgia, 30322, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.39mL

0.28mL

0.14mL

6.96mL

1.39mL

0.70mL

13.91mL

2.78mL

1.39mL

References

 

Historical Records

Categories